Medication-related osteonecrosis of the jaw related to epacadostat and pembrolizumab

Decaux, Jérôme;Magremanne, Michèle
(2020) Journal of Stomatology, Oral and Maxillofacial Surgery — Vol. S2468-7855, n° 20, p. 30095-30091 (2020)

Files

MRONJpembroepacadostat.pdf
  • Open Access
  • Adobe PDF
  • 936.22 KB
Download

Details

Authors
Abstract
MRONJ is a well-known side effect of various medications, such as antiresorptive drugs, anti-angiogenic agents, immunomodulators and immunosuppressants. MRONJ related to immunotherapy is rarely described, with only one case related to ipilimumab. The interaction between the immune system and osteoclast lineage cells is well known. T cells release factors and cytokines that control osteoclastogenesis, and osteoclasts produce factors with an action on T cells. We attempted to explain how immunotherapy could cause MRONJ through the case report of a young patient with metastatic melanoma who developed maxilla MRONJ after pembrolizumab and epacadostat treatment.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Decaux, J., & Magremanne, M. (2020). Medication-related osteonecrosis of the jaw related to epacadostat and pembrolizumab. Journal of Stomatology, Oral and Maxillofacial Surgery, S2468-7855(20), 30095-30091. https://doi.org/10.1016/j.jormas.2020.05.001 (Original work published 2020)